Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.87
ZGNX's Cash to Debt is ranked higher than
63% of the 1173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. ZGNX: 0.87 )
ZGNX' s 10-Year Cash to Debt Range
Min: 0.29   Max: N/A
Current: 0.87

Equity to Asset 0.19
ZGNX's Equity to Asset is ranked lower than
52% of the 983 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ZGNX: 0.19 )
ZGNX' s 10-Year Equity to Asset Range
Min: -3.87   Max: 0.54
Current: 0.19

-3.87
0.54
F-Score: 4
Z-Score: -1.75
M-Score: 2.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6.88
ZGNX's Operating margin (%) is ranked higher than
54% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. ZGNX: -6.88 )
ZGNX' s 10-Year Operating margin (%) Range
Min: -299.29   Max: -49.44
Current: -6.88

-299.29
-49.44
Net-margin (%) 17.77
ZGNX's Net-margin (%) is ranked higher than
91% of the 1117 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. ZGNX: 17.77 )
ZGNX' s 10-Year Net-margin (%) Range
Min: -313.81   Max: 21.19
Current: 17.77

-313.81
21.19
ROE (%) 15.28
ZGNX's ROE (%) is ranked higher than
85% of the 1157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.46 vs. ZGNX: 15.28 )
ZGNX' s 10-Year ROE (%) Range
Min: -491.54   Max: 23.3
Current: 15.28

-491.54
23.3
ROA (%) 4.60
ZGNX's ROA (%) is ranked higher than
74% of the 1183 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.53 vs. ZGNX: 4.60 )
ZGNX' s 10-Year ROA (%) Range
Min: -89.81   Max: 5.45
Current: 4.6

-89.81
5.45
ROC (Joel Greenblatt) (%) -23.23
ZGNX's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1178 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.83 vs. ZGNX: -23.23 )
ZGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -509.09   Max: -169.61
Current: -23.23

-509.09
-169.61
Revenue Growth (3Y)(%) -31.70
ZGNX's Revenue Growth (3Y)(%) is ranked lower than
51% of the 971 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. ZGNX: -31.70 )
ZGNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -31.7
Current: -31.7

» ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ZGNX Guru Trades in Q2 2014

Chuck Royce 734,478 sh (unchged)
» More
Q3 2014

ZGNX Guru Trades in Q3 2014

Jim Simons 501,280 sh (New)
Chuck Royce 734,478 sh (unchged)
» More
Q4 2014

ZGNX Guru Trades in Q4 2014

Jim Simons 644,132 sh (+28.50%)
Chuck Royce Sold Out
» More
Q1 2015

ZGNX Guru Trades in Q1 2015

Paul Tudor Jones 117,800 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.90
ZGNX's P/E(ttm) is ranked higher than
89% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.60 vs. ZGNX: 18.90 )
ZGNX' s 10-Year P/E(ttm) Range
Min: 17.81   Max: 73.04
Current: 18.9

17.81
73.04
PE(NRI) 9.30
ZGNX's PE(NRI) is ranked higher than
98% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 57.50 vs. ZGNX: 9.30 )
ZGNX' s 10-Year PE(NRI) Range
Min: 8.67   Max: 12.92
Current: 9.3

8.67
12.92
P/B 6.10
ZGNX's P/B is ranked higher than
53% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. ZGNX: 6.10 )
ZGNX' s 10-Year P/B Range
Min: 2.5   Max: 202
Current: 6.1

2.5
202
P/S 5.45
ZGNX's P/S is ranked lower than
52% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. ZGNX: 5.45 )
ZGNX' s 10-Year P/S Range
Min: 0.33   Max: 15.16
Current: 5.45

0.33
15.16
EV-to-EBIT -84.42
ZGNX's EV-to-EBIT is ranked higher than
53% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.19 vs. ZGNX: -84.42 )
ZGNX' s 10-Year EV-to-EBIT Range
Min: -113.1   Max: 17.4
Current: -84.42

-113.1
17.4
Current Ratio 1.23
ZGNX's Current Ratio is ranked higher than
54% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. ZGNX: 1.23 )
ZGNX' s 10-Year Current Ratio Range
Min: 0.85   Max: 3.24
Current: 1.23

0.85
3.24
Quick Ratio 0.94
ZGNX's Quick Ratio is ranked higher than
56% of the 1051 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. ZGNX: 0.94 )
ZGNX' s 10-Year Quick Ratio Range
Min: 0.32   Max: 2.54
Current: 0.94

0.32
2.54
Days Inventory 173.81
ZGNX's Days Inventory is ranked higher than
65% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 145.57 vs. ZGNX: 173.81 )
ZGNX' s 10-Year Days Inventory Range
Min: 133.82   Max: 419.33
Current: 173.81

133.82
419.33
Days Sales Outstanding 15.82
ZGNX's Days Sales Outstanding is ranked higher than
96% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 91.38 vs. ZGNX: 15.82 )
ZGNX' s 10-Year Days Sales Outstanding Range
Min: 46.47   Max: 79.94
Current: 15.82

46.47
79.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
ZGNX's Price/Median PS Value is ranked higher than
81% of the 1290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. ZGNX: 1.30 )
ZGNX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 2.61
Current: 1.3

0.12
2.61
Earnings Yield (Greenblatt) -1.20
ZGNX's Earnings Yield (Greenblatt) is ranked higher than
54% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ZGNX: -1.20 )
ZGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.2   Max: 20.4
Current: -1.2

-1.2
20.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:Z08.Germany,
Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Its trademarks include DosePro, Relday, Zogenix and Zohydro ER. The Company is subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
comment on ZGNX Mar 23 2013 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
ZOGENIX, INC. Financials May 20 2015
10-Q for Zogenix, Inc. May 13 2015
Zogenix reports 1Q loss May 11 2015
Zogenix reports 1Q loss May 11 2015
Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results May 11 2015
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2015
Zogenix Provides Corporate Update and Reports First Quarter 2015 Financial Results May 11 2015
Q1 2015 Zogenix Inc Earnings Release - After Market Close May 11 2015
10-K for Zogenix, Inc. May 06 2015
Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11 May 04 2015
Zogenix to Release First Quarter 2015 Financial Results and Host Conference Call & Webcast on May 11 May 04 2015
ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Apr 28 2015
Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS... Apr 27 2015
ZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 27 2015
Dr. Stephen Farr Appointed as CEO of Zogenix to Lead New Strategic Focus and Advance Late-Stage CNS... Apr 27 2015
Zogenix Closes Sale of Zohydro(R) ER Business to Pernix Apr 24 2015
Zogenix Closes Sale of Zohydro(R) ER Business to Pernix Apr 24 2015
Coverage initiated on Zogenix by Piper Jaffray Apr 22 2015
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study Mar 26 2015
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK